How rich is Patrick Soon-Shiong?
Patrick Soon-Shiong Net Worth:
|Birth date:||July 29, 1952|
|Birth place:||Port Elizabeth, South Africa|
|Profession:||CEO of NantHealth|
|Education:||University of the Witwatersrand, University of California, Los Angeles, University of British Columbia|
Patrick Soon-Shiong net worth, wiki & biography:
Patrick Soon-Shiong is a South African born American surgeon, medical research worker, businessman, philanthropist, and also a professor at University of California, Los Angeles. He has an estimated net worth of $8 billion as of March 2013 — #143 on Forbes Billionaires List, #48 in the USA and #400 in Forbes 400 List as of 2012. Forbes also rated him as the most affluent American in the health care industry and in Los Angeles. He is most commonly known for developing the metatastic breast cancer treatment drug. He is the current Chairman of the Chan Soon-Siong Family Foundation, and Chairman and CEO of the Chan Soon-Siong Institute for Advanced Health, National LambdaRail, the Healthcare Transformation Institute, and NantWorks, LLC. He is also the minority owner of the Los Angeles Lakers.
Patrick Soon-Shiong Net Worth $8 Billion
At the age of 16, he graduated from high school. He received his medical degree at 23 from the University of Witwatersrand where he was fourth out of 189. After finishing his internship at Johannesburg’s General Hospital, he earned a Master of Science degree in the University of British Columbia. Then he moved to the United States and trained at UCLA where he became a board certified surgeon. Dr. Soon-Shiong is a Fellow of the Royal College of Surgeons (Canada) and a Fellow of the American College of Surgeons.
Dr. Soon-Shiong has assembled and then sold two successful drug companies. Dr. Soon-Shiong took American Pharmaceutical Partnership (APP) public in 2001 and founded a new firm, Abraxis, in 2007. In 2008, Dr. Soon-Shiong sold APP for $6.5 billion to Germany’s Fresenius. In 2010, Dr. Soon-Shiong sold Abraxis to Celgene for $2.9 billion. Dr. Soon-Shiong founded NantWorks in 2011 and is taking care of the brand new cancer therapies. In the year 2012, Blackstone Group Invested $125 million for a position in the NantPharma unit. As a philanthropist, he is an associate of the Giving Pledge.